Close Menu

NEW YORK (GenomeWeb) – Illumina reported after the close of the market on Tuesday that its first quarter 2018 revenues climbed 31 percent.

The San Diego, California-based genomic technologies company reported total Q1 revenues of $782 million compared to $598 million in Q1 2017, beating analysts' average estimate of $743.5 million.

Total Q1 2018 revenue included $628 million in product revenue and $154 million in service and other revenue, up from $491 million and $107 million, respectively, in the previous year's quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Wired reports on how genetic genealogy's use in forensics has exploded in the year since an arrest in the Golden State Killer case was made.

New York City has settled with a forensic scientist who was fired after questioning a DNA testing approach used by the medical examiner's office, the New York Times reports.

Retraction Watch reports that the increase in retracted papers at a journal is due to more resources there to tackle publication ethics.

In Nature this week: technique for measuring replication fork movement, WINTHER trial results, and more.

Apr
30
Sponsored by
Lexogen

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May
01
Sponsored by
Illumina

This webinar will discuss the benefits of virus-specific target capture combined with next-generation sequencing (NGS) to identify viral infections and conduct comprehensive genomic and transcriptomic interrogation.

May
07
Sponsored by
Agilent

This webinar will discuss the implementation of an enterprise-wide clinical genomics platform that is shared across 10 hospitals and research organizations in the Australian State of Victoria.

May
08
Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.